Dr. Tsui-Fen Chou's research interests include chemical biology, cancer cell biology, medicinal chemistry, biochemistry, quantitative proteomics, yeast genetics and high-throughput screening. Her main research focus is on discovering underlying mechanisms that may lead to new therapeutic targets for cancer.
Selected Cancer-Related Publications:
Chou TF, Li K, Frankowski KJ, Schoenen FJ, Deshaies RJ. Structure-activity relationship study reveals ML240 and ML241 as potent and selective inhibitors of p97 ATPase. ChemMedChem. 2013 Feb;8(2):297-312. doi: 10.1002/cmdc.201200520. Epub 2013 Jan 11.
Chou TF, Deshaies RJ. Quantitative cell-based protein degradation assays to identify and classify drugs that target the ubiquitin-proteasome system. J Biol Chem. 2011 May 13;286(19):16546-54. doi: 10.1074/jbc.M110.215319. Epub 2011 Feb 22.
Chou TF, Brown SJ, Minond D, Nordin BE, Li K, Jones AC, Chase P, Porubsky PR, Stoltz BM, Schoenen FJ, Patricelli MP, Hodder P, Rosen H, Deshaies RJ. Reversible inhibitor of p97, DBeQ, impairs both ubiquitin-dependent and autophagic protein clearance pathways. Proc Natl Acad Sci U S A. 2011 Mar 22;108(12):4834-9. doi: 10.1073/pnas.1015312108. Epub 2011 Mar 7.
Chou TF, Deshaies RJ. Development of p97 AAA ATPase inhibitors. Autophagy. 2011 Sep;7(9):1091-2. Epub 2011 Sep 1.